25 Results for "

db/db mice

" in MedChemExpress (MCE) Product Catalog:
Products (25)

25 Results for "db/db mice" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-18555
CAS No.: 1258275-73-8
TMPA is a high-affinity Nur77 antagonist that binds to Nur77 leading to the release and shuttling of LKB1 in the cytoplasm to activate AMPKα. TMPA effectively lowers blood glucose and attenuates insulin resistance in type II db/db, high-fat diet and streptozotocin-induced diabetic mice. TMPA reduces RICD (restimulation-induced cell death) in human T cells, can also be used in studies of cancer and T-cell apoptosis dysregulation .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-161834
CAS No.: 2140901-88-6
RG100204 is a selective, orally available inhibitor of the aquaporin AQP9. RG100204 directly inhibits AQP9 channel function, preventing the transmembrane transport of water, glycerol, and H 2O 2. RG100204 reduces the activation of the NLRP3 inflammasome and p38 MAPK signaling pathways, thereby alleviating inflammation and pyroptosis. RG100204 reduces multi-organ dysfunction in a mouse sepsis model and shows glucose-regulating effects in diabetic db/db mice .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-112234
CAS No.: 17094-01-8
Synonyms: Sepiapterin
L-Sepiapterin (Sepiapterin), is a phenylalanine hydroxylase activator, is a precursor of the endothelial nitric oxide synthase (eNOS) cofactor tetrahydrobiopterin (BH4). L-Sepiapterin improves endothelial dysfunction in small mesenteric arteries from db/db mice, and induces angiogenesis. L-Sepiapterin inhibits cell proliferation and migration of ovarian cancer cells via down-regulation of p70 S6K-dependent VEGFR-2 expression. L-Sepiapterin can be used for the study of hyperphenylalaninemia .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-153617
CAS No.: 2451093-95-9
Purity:  99.05%
Target:  

FOXO

Research Areas:  

Metabolic Disease

FOXO1-IN-3 is a highly-selective and orally active FOXO1 inhibitor. FOXO1-IN-3 reduces hepatic glucose production in mice. FOXO1-IN-3 improves insulin sensitivity and glucose control in db/db mice without causing weight gain .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-17604
CAS No.: 1118567-05-7
Synonyms: EGT1442; EGT0001442; THR-1442
Target:  

SGLT

Bexagliflozin (EGT1442) is an orally active and selective SGLT2 inhibitor with IC50 values of 0.002 μM and 5.6 μM for SGLT2 and SGLT1, respectively. Bexagliflozin selectively inhibits SGLT2-mediated sodium-dependent glucose uptake. Bexagliflozin induces saturable urinary glucose excretion in normal rats and dogs. Bexagliflozin reduces blood glucose and HbA1c levels in db/db mice without affecting body mass or insulin level. Bexagliflozin can be used for the research of type 2 diabetes mellitus, hypertensive stroke .
loading...
    loading...
Cat. No.: HY-113365
CAS No.: 601-57-0
Purity:  99.81%
Synonyms: 4-Cholesten-3-one
Cholestenone (4-cholesten-3-one) is an orally available antimicrobial agent that is metabolized primarily in the liver as an intermediate oxidation product of cholesterol. Cholestenone inhibits human dermal fibroblast migration and fights Helicobacter pylori infection in vitro and in mouse models by inhibiting cholesterol-α-D-glucopyranoside (CGL). Cholestenone also alleviates metabolic disorders caused by obesity in db/db mice .
loading...
    loading...
Cat. No.: HY-101064S3
CAS No.: 1190594-22-9
Purity:  98.90%
Fmoc-leucine-d10 is the deuterium labeled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity .
loading...
    loading...
Cat. No.: HY-131334
CAS No.: 2493239-46-4
Purity:  99.18%
Target:  

AMPK

Research Areas:  

Metabolic Disease

AMPK activator 4 is a potent AMPK activator without inhibition of mitochondrial complex I. AMPK activator 4 selectively activates AMPK in the muscle tissues. AMPK activator 4 dose-dependently improves glucose tolerance in normal mice, and significantly lowers fasting blood glucose level and ameliorates insulin resistance in db/db diabetic mice. Anti-hyperglycemic effect .
loading...
    loading...
Cat. No.: HY-101064S2
CAS No.: 538372-74-6
Purity:  98.50%
Synonyms: N-FMOC-leucine-d3; NPC 15199-d3; NSC 334290-d3
Fmoc-leucine-d3 is the deuterium labeled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity .
loading...
    loading...
Cat. No.: HY-P99959
CAS No.: 2379805-59-9
Synonyms: MT-3921; rH116A3

Target:  

TGF-β Receptor

Research Areas:  

Neurological Disease

Unasnemab (MT-3921) is a humanised IgG1 monoclonal antibody that binds to repulsive guidance molecule A (RGMa). Unasnemab improves locomotor function and promotes neuroregeneration. Unasnemab exerts ameliorative effects on hippocampal neurogenesis impairment and cognitive decline in db/db mice, Streptozotocin (STZ) (HY-13753)-induced type 1 diabetic and bilateral common carotid artery stenosis (BCAS)-induced mice. Unasnemab can be used for the research of spinal cord injury, diabetes-induced neurological impairments .
loading...
    loading...
Cat. No.: HY-124244
CAS No.: 1257641-15-8
Synonyms: PPARδ/γ agonist 1
Target:  

PPAR

Research Areas:  

Neurological Disease

DB-959 (PPARδ/γ agonist 1) is a potent PPAR agonist targeting PPARδ/γ. DB-959 improves spatial learning and memory in mice induced by Streptozotocin (HY-13753) and has the potential to improve Alzheimer's disease (AD). .
loading...
    loading...
Cat. No.: HY-17538A
CAS No.: 2319647-97-5
Target:  

PGC-1α

Research Areas:  

Metabolic Disease

ZLN005 (hydrochloride) is a peroxisome proliferator-activated receptor-g coactivator-1a (PGC-1α) activator. ZLN005 (hydrochloride) can stimulate the expression of PGC-1α and downstream genes in skeletal muscle cells, improve glucose utilization and fatty acid oxidation. ZLN005 (hydrochloride) can increase the transcription of PGC-1α and downstream genes in skeletal muscle of diabetic db/db mice, increase fat oxidation and improve glucose tolerance, pyruvate tolerance and insulin sensitivity .
loading...
    loading...
Cat. No.: HY-P10312
Target:  

GLP Receptor

Research Areas:  

Metabolic Disease

SPN009 (Sequence 3) is a GLP-1 Receptor agonist, with EC50 of 2.84 nM. SPN009 attenuates the type II diabetes in DB/DB mice models .
loading...
    loading...
Cat. No.: HY-P5578
CAS No.: 753024-08-7
Target:  

GCGR

Research Areas:  

Metabolic Disease

A8SGLP-1 is an orally active GLP-1 analogue that the alanine at position 8 substituted with serine. A8SGLP-1 reduces blood glucose in db/db mice without affecting its function .
loading...
    loading...
Cat. No.: HY-P5578A
Target:  

GCGR

Research Areas:  

Metabolic Disease

A8SGLP-1 TFA is an orally active GLP-1 analogue that the alanine at position 8 substituted with serine. A8SGLP-1 TFA reduces blood glucose in db/db mice without affecting its function .
loading...
    loading...
Cat. No.: HY-117446
CAS No.: 1395553-32-8
Target:  

GPR119

Research Areas:  

Metabolic Disease

AS-1669058 is a GPR119 agonist and a potential inhibitor of type 2 diabetes. AS-1669058 induces insulin secretion in response to high blood glucose levels in vitro and in vivo and increases insulin promoter activity. In animal studies, AS-1669058 improved glucose tolerance and reduced blood glucose levels in db/db mice .
loading...
    loading...
Cat. No.: HY-117446A
CAS No.: 1395553-31-7
Target:  

GPR119

Research Areas:  

Metabolic Disease

AS-1669058 free base is a GPR119 agonist and a potential inhibitor of type 2 diabetes. AS-1669058 free base induces insulin secretion induced by high blood glucose levels in vitro and in vivo and increases insulin promoter activity. In animal studies, AS-1669058 free base improved glucose tolerance and reduced blood glucose levels in db/db mice.
loading...
    loading...
Cat. No.: HY-138842
CAS No.: 118006-14-7
Target:  

Insulin Receptor Akt ERK

Research Areas:  

Metabolic Disease

DDN is a selective insulin receptor (Insulin Receptor) activator, an insulin sensitizer, and a glucose-lowering insulin mimetic with oral bioavailability. DDN can directly bind to the receptor kinase domain and induce Akt and ERK phosphorylation, and it can also enhance insulin's effect on glucose uptake. DDN significantly reduces blood glucose levels in wild-type and diabetic ob/ob and db/db mice .
loading...
    loading...
Cat. No.: HY-161926
CAS No.: 2835447-74-8
Target:  

PPAR

Research Areas:  

Metabolic Disease

YGT-31 is a modulator for PPARγ with an IC50 of 1.72 μM, and a Ki of 0.62 μM. YGT-31 reduces blood glucose levels and improves insulin resistance in db/db mice type 2 diabetes models, through inhibition of CDK5-mediated PPARγ-Ser273 phosphorylation. YGT-31 exhibits anti-hepatic steatosis effect in mice non-alcoholic fatty liver disease (NAFLD) model .
loading...
    loading...
Cat. No.: HY-114598
CAS No.: 152595-59-0
Target:  

SGLT

Research Areas:  

Metabolic Disease

WAY-123783 is a potent, selective and orally active sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor producing activity after metabolism. WAY-123783 can increase the excretion of sugar in urine and at the same time lower the blood sugar level in db/db mice (ED50 = 9.85 mg/kg). WAY-123783 can be used for the research of metabolic disease, such as diabetes .
loading...
    loading...